Albemarle ( ALB) said it has been named as one of the production partners in the supply of intermediate chemicals for the antiviral Tamiflu, produced by Roche of Basel, Switzerland. Richmond, Va.-based Albemarle said it was selected on the basis of its ability to produce substantial quantities of intermediates and finished materials in accordance with Roche's quality standards in a relatively short time frame. "The need to respond to the growing demand for Tamiflu is one of the most important challenges facing the life sciences industry today. We believe that our selection by Roche for this cGMP manufacturing opportunity is further validation of Albemarle's Fine Chemistry Services capabilities, and we are striving to do our part to ensure that the public health needs for this important product are satisfied completely," the company said. CGMP are the current Good Manufacturing Practices followed by pharmaceutical and biotech firms to ensure that their products and intermediates used to make the final products meet specific requirements for identity, strength, quality and purity.